That's up 9M I believe. The scarry part is that they revised dacogen revenues to $55M. That's an additional $5m less. Looks like Dcaogen sales in the EU grew by $6M+ this quarter. Giving ASTX an addition $2M increase in revenues. As always there will be a hangover on generic dacogen. See if we learn anything in the update.